Safety, Tolerability, and Immunogenicity of NeomiVac, a Next-Generation mRNA–Lipid Nanoparticle Vaccine Comprising a Novel Ionisable Lipid: A First-In-Human, Phase 1, Dose-Escalation Trial

SSRN Electronic Journal 2026 Preprint Open access

Read full text
Authors: Angelica Vaccaro, Jordon Rolt, Nicole Frumento, Ola Diebold, Stephen M. Laidlaw, Susanna Shier, A. C. Brown, Clement Twumasi, Victoria Walker, Heinrich Haas, James Smith, Manuela Zonca
+17 more Hannah Emami, Eran Eilat, Fatemeh Moussavi-Pourgharbi, Alison M. Lawrie, Caroline A. Maxwell, Mwila Kasanyinga, Nicola M. Greenwood, Srinivas Ramishetti, Denis Bešić, Surender Vashist, Jan Egberts, César López‐Camacho, Adrian V. S. Hill, Dan Peer, Miles W. Carroll, Eleanor J. Barnes, Paola Cicconi
DOI: 10.2139/ssrn.6134910
Cited by: 0

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research RNA Interference and Gene Delivery Immunotherapy and Immune Responses

Publication details

Journal / source
SSRN Electronic Journal
Publication date
1 January 2026
Document type
Preprint